Heart surgery showdown: which solution saves more heart muscle?
NCT ID NCT07637266
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two solutions used to protect the heart during coronary artery bypass surgery: standard blood cardioplegia and del Nido cardioplegia. Researchers will use MRI scans to see which solution better preserves heart muscle. The trial involves 60 adults with multivessel coronary artery disease scheduled for elective bypass surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Del Nido cardioplegia solution and blood cardioplegia solution
- What this could lead to
- If one solution proves better, it could guide surgeons toward a safer method for protecting the heart during bypass surgery.
- What could go wrong
- This is a small, early-stage study with only 60 patients, so results may not apply to everyone. The main goal is to gather knowledge, not to prove a new treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Eligibility Criteria: 1\. Patients with multivessel coronary artery disease scheduled for elective coronary artery bypass grafting Exclusion Criteria: 1. Left ventricular ejection fraction \<30% 2. Associated cardiac procedures 3. Off-pump coronary artery bypass grafting 4. Contraindications for MRI 5. Inability to provide consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CABG are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Hospital Center Zagreb
RECRUITINGZagreb, 10000, Croatia
-
University Hospital Center Zagreb
RECRUITINGZagreb, 10000, Croatia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Pre-Surgery nerve block stop years of chest pain after heart surgery?
- Can ancient herbs speed up heart surgery recovery?
- Can a neck nerve block calm the Body's inflammatory storm after heart surgery?
- Could skipping the breathing tube speed heart surgery recovery?
- Timing is everything: could physiotherapy minutes after extubation prevent lung complications?
- Pre-surgery exercise program may help high-risk heart patients leave the hospital sooner